Table 4 One-year clinical outcomes
Morphine group (n = 45) | Placebo group (n = 43) | P value | |
|---|---|---|---|
Major adverse cardiac events, n (%) | 7 (15.6) | 8 (18.6) | 0.70 |
Cardiovascular death | 0 (0.0) | 1 (2.3) | |
Heart failure | 2 (4.4) | 2 (4.6) | |
STEMI | 1 (2.2) | 1 (2.3) | |
Stable angina | 3 (6.7) | 3 (7.0) | |
Sustained ventricular arrhythmia | 1 (2.2) | 1 (2.3) | |
Other clinical events, n (%) | 5 (11.1) | 4 (9.3) | 0.78 |
Non-cardiovascular death | 1 (2.2) | 0 (0.0) | |
CABG | 1 (2.2) | 2 (4.6) | |
Elective PCI | 3 (6.7) | 2 (4.6) |